Mariner, LLC Affimed N.V. Transaction History

Mariner, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$0.57 - $1.08 $1,339 - $2,538	-2,350 Reduced 16.06%	12,282 $7,000
Q1 2023 May 12, 2023	SELL	$0.66 - $1.29 $1,648 - $3,222	-2,498 Reduced 14.58%	14,632 $11,000
Q4 2022 Feb 14, 2023	BUY	$1.1 - $2.45 $100 - $222	91 Added 0.53%	17,130 $21,000
Q3 2022 Nov 10, 2022	BUY	$1.96 - $3.32 $33,396 - $56,569	17,039 New	17,039 $35,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

Stay updated on Mariner, LLC with notifications on news.